When was Wheeler Bio founded?

Wheeler Bio was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Wheeler Bio located?

Wheeler Bio is headquartered in Oklahoma City, United States.

How many employees does Wheeler Bio have?

As of Apr 30, 2026, the latest employee count at Wheeler Bio is 73.

Is Wheeler Bio a funded company?

Wheeler Bio is a funded company, having raised a total of $103M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 11, 2022.

When was the latest funding round of Wheeler Bio?

Wheeler Bio's latest funding was a $***** Series A round on Mar 04, 2025, with participation from 5 investors.

Where does Wheeler Bio rank among its competitors?

Wheeler Bio ranks 6th amongst 275 active competitors, of which 18 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Kardigan, which secured $254M in Oct, 2025.

Who are the top competitors of Wheeler Bio?

Wheeler Bio's top competitors include Aragen, OneSource and Kardigan. Among them, Kardigan secured the most recent funding round in October, 2025.

Wheeler Bio - 2026 Company Profile, Team, Funding & Competitors

Wheeler Bio is a series A company based in Oklahoma City (United States), founded in 2020. It operates as a Provider of drug research and analytical development services for multiple therapeutic areas. Wheeler Bio has raised $103M in funding from investors like Echo, Charles River Laboratories and Alloy Therapeutics. The company has 275 active competitors, including 18 funded and 20 that have exited. Its top competitors include companies like Aragen, OneSource and Kardigan.

Key Metrics

Founded Year

2020

Location

Oklahoma City, United States

Stage

Series A

Total Funding

$103M in 5 rounds

Latest Funding Round

Series A, Mar 04, 2025, $*****

Investors

Echo & 14 more

Ranked

6^th among 275 active competitors

Employee Count

73 as on Apr 30, 2026

Similar Companies

Aragen & 279 more

View Wheeler Bio's full profile

Wheeler Bio has raised a total funding of $103M over 5 rounds. Its first funding round was on Jan 11, 2022. Its latest funding round was a Series A round on Mar 04, 2025 for $*****. 5 investors participated in its latest round. Wheeler Bio has 15 institutional investors.

Here is the list of recent funding rounds of Wheeler Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2025	6817760	Series A	6116012	1616294	1860517	5950799
Apr 13, 2023	8786385	Series A	4145242	3198398	1629986	Atum Capital & 5 more
Jan 12, 2023	6876759	Series A	9652642	7177269	Boyd Street Ventures	6699330

Access funding benchmarks and valuations. Sign up today!

View details of Wheeler Bio's funding rounds and investors

Wheeler Bio's employee count trend

Wheeler Bio has 73 employees as of Apr 26. Here is Wheeler Bio's employee count trend over the years:

Uncover Wheeler Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Wheeler Bio include Aragen, OneSource and Kardigan. Here is the list of Top 10 competitors of Wheeler Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Aragen 2001, Hyderabad (India), Series B	Provider of drug discovery, clinical development, manufacturing, and other services for small molecules	$161M	Quadria Capital, Sequoia Capital & 18 others	68/100
2nd	OneSource 1990, Bengaluru (India), Public	Pharmaceutical contract development and manufacturing organization offering pharmaceutical products	$155M	Erasmic Venture Fund, Accel & 14 others	59/100
3rd	Kardigan 2023, San Francisco (United States), Series B	Biotech company developing personalized medicines for cardiovascular diseases	$554M	Perceptive Advisors, Sequoia Heritage & 3 others	57/100
4th	Vectura 1997, Chippenham (United Kingdom), Acquired	Developer of inhaled therapeutics for respiratory diseases	$15.2M	HBM Healthcare Investments, Boehringer Ingelheim ... & 5 others	54/100
5th	Suanfarma 1993, Madrid (Spain), Acquired	Developer of generics, nutraceuticals, and APIs	-	Hermes GPE	54/100
6th	Wheeler Bio 2020, Oklahoma City (United States), Series A	Provider of drug research and analytical development services for multiple therapeutic areas	$103M	Floating Point, Atum Capital & 13 others	52/100
7th	Quotient Sciences 1990, Nottingham (United Kingdom), Acquired	Developer and manufacturer of APIs as well as finished dosage forms	-	GHO Capital Partners	52/100
8th	Nephron Pharmaceuticals 1937, Florida (Puerto Rico), Late Stage	Manufacturer of sterile pharmaceutical products and provider of contract manufacturing and 503B outsourcing services	$625M	Blackrockbkcc, PNC & 3 others	51/100
9th	revalia bio 2021, New Haven (United States), Seed	Provider of contract based drugs development services for biopharma sector	$26.8M	Sierra Ventures, AFF & 3 others	50/100
10th	Aiolos Bio 2023, Boston (United States), Acquired	Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions	$245M	Atlas Venture, Bain Capital Life Sciences ... & 3 others	48/100